Overview

A Double-blind, Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3 multicenter, double blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)

Phase:

Phase 3

Details

Lead Sponsor:

Moberg Pharma AB

Collaborator:

IQVIA Biotech